#ELI LILLY $LLY back to ATH! What's next for LLY (Long term).

Eli Lilly (LLY) stock jumped more than 3% to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%.
LLY is climbing back toward its record high of 966.10 reached on July 15.

The three-year study of patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients treated with a placebo.

Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%.

This is very bullish news for LLY. This is easily a 1k stock and a good long term investment if you want exposure to the Glucagon-like peptide-1 meds (GLP-1). LLY is number one in that field hands down.

Consensus around 100bn, current 950.

Research material for you:
Alzheimer's potential benefits.
Novo data (NVO), 2025.